Literature DB >> 22121166

FDA cancels approval for bevacizumab in advanced breast cancer.

Janice Hopkins Tanne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22121166     DOI： 10.1136/bmj.d7684

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

Review 1.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

Review 2.  Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).

Authors:  Laura Cosmai; Maurizio Gallieni; Wanda Liguigli; Camillo Porta
Journal:  J Nephrol       Date:  2016-05-06       Impact factor: 3.902

Review 3.  The role of the neural niche in brain metastasis.

Authors:  Reid Hoshide; Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2017-09-13       Impact factor: 5.150

4.  Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.

Authors:  Esak Lee; Jacob E Koskimaki; Niranjan B Pandey; Aleksander S Popel
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

Review 5.  Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.

Authors:  Efstathios T Pavlidis; Theodoros E Pavlidis
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

6.  Anti-VEGF therapy revived by c-Met inhibition, but is c-Met the answer?

Authors:  Kristi D Lynn; Rolf A Brekken
Journal:  Cancer Discov       Date:  2012-03       Impact factor: 39.397

7.  Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Bin Lian; Wei-Ping Yang; Chang-Yuan Wei
Journal:  Exp Ther Med       Date:  2014-03-05       Impact factor: 2.447

8.  Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5.

Authors:  Prisca Exertier; Sophie Javerzat; Baigang Wang; Mélanie Franco; John Herbert; Natalia Platonova; Marie Winandy; Nadège Pujol; Olivier Nivelles; Sandra Ormenese; Virginie Godard; Jürgen Becker; Roy Bicknell; Raphael Pineau; Jörg Wilting; Andreas Bikfalvi; Martin Hagedorn
Journal:  Oncotarget       Date:  2013-12

Review 9.  Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review).

Authors:  Stefan Langhammer
Journal:  Oncol Rep       Date:  2013-07-22       Impact factor: 3.906

Review 10.  Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.

Authors:  Bhavesh K Ahir; Herbert H Engelhard; Sajani S Lakka
Journal:  Mol Neurobiol       Date:  2020-03-09       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.